Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Are These Stocks Deep in Red Today?

Page 1 of 2

Although the three major indexes have each opened 1% higher, a number of stocks have lost ground in Tuesday intraday trading.

Among the losers today are Regulus Therapeutics Inc (NASDAQ:RGLS), Vista Gold Corp. (NYSEMKT:VGZ), Babcock & Wilcox Enterprises Inc (NYSE:BW), Barrick Gold Corporation (USA) (NYSE:ABX), and COMSCORE, Inc. (NASDAQ:SCOR). In this article, we analyze why traders are selling and see how the funds in our database are positioned towards them.

Hedge fund sentiment is an important metric for assessing the long-term profitability. At Insider Monkey, we track over 700 hedge funds, whose quarterly 13F filings we analyze and determine their collective sentiment towards several thousand stocks. However, our research has shown that the best strategy is to follow hedge funds into their small-cap picks. This approach can allow monthly returns of nearly 95 basis points above the market, as we determined through extensive backtests covering the period between 1999 and 2012 (see the details here).

gold-296115_1280

Regulus’ RG-101 on Clinical Hold

Regulus Therapeutics Inc (NASDAQ:RGLS) shares have fallen almost 50% after the FDA verbally notified the biotech that its IND for lead drug candidate RG-101 has been placed on full clinical hold. The FDA put the IND on hold after Regulus reported a second serious adverse event of jaundice. RG-101 is a potential drug candidate for the treatment of chronic hepatitis C virus. Of the 766 funds we track, 14 funds owned $24.95 million worth of Regulus Therapeutics Inc (NASDAQ:RGLS)’s stock, which accounted for 6.80% of the float on March 31, versus 13 funds and $47.35 million, respectively, on December 31.

Follow Regulus Therapeutics Inc. (NASDAQ:RGLS)
Trade (NASDAQ:RGLS) Now!

Babcock & Wilcox Trims Guidance

Babcock & Wilcox Enterprises Inc (NYSE:BW) shares are 21% lower after the company cut its fiscal 2016 adjusted EPS guidance to $0.63-$0.83 from $1.25-$1.45. Analysts were expecting $1.38 per share on sales of $1.8 billion. One reason for the lower EPS guidance is that Babcock will proactively restructure its power business to adjust for lower U.S. coal generation. The company will eliminate over 200 positions in North America immediately and undertake other cost saving measures to make its coal business more efficient and cost competitive. Another reason for the lower guidance is a charge to correct an engineering design error for a new build renewable energy plant in Europe.  The number of funds in our database with holdings in Babcock & Wilcox Enterprises Inc (NYSE:BW) rose by four quarter-over-quarter to 26 at the end of March.

Follow Babcock & Wilcox Enterprises Inc.
Trade (BW) Now!

On the next page, we find out why traders are selling Vista Gold, Barrick Gold Corporation (USA), and COMSCORE Inc.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!